TZP · Incretin & metabolic
Tirzepatide
A 39-amino-acid synthetic peptide engineered as a dual agonist of the GIP and GLP-1 receptors. Its sequence is based on native GIP, with a C20 fatty diacid attached at Lys20 through a linker. The diacid binds albumin and extends circulating half-life.
- Molecular weight
- 4813.5 g/mol
- Formula
- C225H348N48O68
- CAS
- 2023788-19-2
- Form
- Lyophilized powder
- Purity (HPLC)
- ≥ 98.0%
- Storage
- 2–8 °C, protect from light
Vial sizeIn stock
1
$112.00$3.73 / mg
Current lot—
Certificate of analysisNo lot in stock
StorageRefrigerated, away from light
For laboratory research use only. Not for use in humans or animals, or for diagnostic purposes.
Mechanism
Tirzepatide binds the GIP receptor with affinity comparable to native GIP, and the GLP-1 receptor with roughly five-fold lower affinity than native GLP-1. This is described as imbalanced agonism. At GLP-1R it favours cAMP generation over β-arrestin recruitment, which may reduce receptor internalization compared with native ligand.
Key findings in the literature
01In diet-induced obese mice, it reduced body weight and food intake more than a selective GLP-1R agonist did [1].
02The Phase 3 SURMOUNT-1 trial reported mean body-weight reductions of 15.0–20.9% at 72 weeks across doses, compared with 3.1% for placebo [2].
03In SURPASS-2, it produced a greater HbA1c reduction than semaglutide 1 mg in adults with type 2 diabetes [3].